期刊
ANTICANCER RESEARCH
卷 39, 期 4, 页码 1711-1718出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13277
关键词
Osteosarcoma; P-Glycoprotein; cisplatin resistance
类别
资金
- Shanghai Ninth People's Hospital Lin+ Program [JYLJ012]
- National Key R&D Program of China [2016YFC1100600]
Background/Aim: Osteosarcoma (OS) is a diagnosed primary cancer of the bone. Despite the great advances that have been made during the past decades in OS therapy, drug resistance and tumor recurrence are still major problems. It is urgent to find novel strategies to overcome drug resistance in order to prolong the survival time of OS patients. Materials and Methods: Cell viability was investigated by the cell count kit-8 (CCK-8) and colony formation assays. P-Glycoprotein (P-gp) expression was analyzed by RT-qPCR and western blot. A xenograft mouse model was used to identify the synergistic efficacy of a P-gp inhibitor with cisplatin. Student's t-test was used to determine statistically significant differences. Results: P-gp expression levels were associated with cisplatin efficacy in OS patients. OS cells with higher P-gp expression were more resistant to cisplatin. Knockdown or inhibition of P-gp sensitized OS cells to cisplatin. Conclusion: Downregulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据